Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback